N Z Med J. 1981 Apr 8;93(681):215-8.
Labetalol was used in a multicentre open clinical trial in 128 patients in 10 centres. Nearly half had had either poor response to other drugs or side effects with them, while another 25 percent had failed to respond satisfactorily to a diuretic alone and 35 percent were previously untreated. The results at one year showed that labetalol had an excellent antihypertensive effect, often successful in patients who had failed to respond adequately to pure beta-blockers or other drugs and it proved easy to use. Side effects necessitated stopping the drug at less than adequate dosage in some patients who might also have proved resistant to labetalol and other drugs were added to improve blood pressure control in 25 patients who continued labetalol. The mean dose of labetalol was 707 mg/day and there was no evidence of tolerance developing. Side effects were fairly common and led to withdrawal of 28 patients (22 percent).
拉贝洛尔在一项多中心开放性临床试验中应用于来自10个中心的128例患者。近一半患者对其他药物反应不佳或出现副作用，另有25%的患者单独使用利尿剂效果不佳，35%的患者此前未接受过治疗。一年的结果显示，拉贝洛尔具有出色的降压效果，对于对单纯β受体阻滞剂或其他药物反应不佳的患者常常有效，而且使用方便。在一些可能对拉贝洛尔耐药的患者中，副作用导致在剂量不足时停药，在继续使用拉贝洛尔的25例患者中加用了其他药物以改善血压控制。拉贝洛尔的平均剂量为707毫克/天，没有出现耐受性的证据。副作用相当常见，导致28例患者（22%）停药。
